RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000069.xml
PDF herunterladen
Semin Liver Dis 2023; 43(02): 226-233
DOI: 10.1055/a-2104-9034
DOI: 10.1055/a-2104-9034
Review Article
Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease
Funding This work was supported by the Hickam Endowed Chair, Gastroenterology, Medicine, Indiana University, the Indiana University Health – Indiana University School of Medicine Strategic Research Initiative, the Career Scientist Award (IK6BX005226) and the VA Merit award (1I01BX003031) to H.F. from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development Service, and NIH grants DK108959 and DK119421 (to H.F.). Portions of these studies were supported by resources at the Richard L. Roudebush VA Medical Center, Indianapolis, IN. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.
Abstract
Mast cells (MCs) contribute to the pathogenesis of cholestatic liver diseases (primary sclerosing cholangitis [PSC] and primary biliary cholangitis [PBC]). PSC and PBC are immune-mediated, chronic inflammatory diseases, characterized by bile duct inflammation and stricturing, advancing to hepatobiliary cirrhosis. MCs are tissue resident immune cells that may promote hepatic injury, inflammation, and fibrosis formation by either direct or indirect interactions with other innate immune cells (neutrophils, macrophages/Kupffer cells, dendritic cells, natural killer, and innate lymphoid cells). The activation of these innate immune cells, usually through the degranulation of MCs, promotes antigen uptake and presentation to adaptive immune cells, exacerbating liver injury. In conclusion, dysregulation of MC-innate immune cell communications during liver injury and inflammation can lead to chronic liver injury and cancer.
Authors' Contributions
J.B. contributed to the drafting and editing the article, figure generation; C.M. contributed to the drafting and editing the article; L.H. contributed to the editing the article and figure generation; H.F. contributed to the funding, editing final draft, and final approval.
Publikationsverlauf
Accepted Manuscript online:
02. Juni 2023
Artikel online veröffentlicht:
05. Juli 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77 (04) 1033-1079
- 2 Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol 2017; 188 (02) 183-194
- 3 Moon TC, Befus AD, Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front Immunol 2014; 5: 569
- 4 Owen JA, Punt J, Stratford S. Kuby Immunology. New York: W.H. Freeman & Company; 2013
- 5 Fukuoka Y, Hite MR, Dellinger AL, Schwartz LB. Human skin mast cells express complement factors C3 and C5. J Immunol 2013; 191 (04) 1827-1834
- 6 Lipitsä T, Naukkarinen A, Laitala J, Harvima IT. Complement C3 is expressed by mast cells in cutaneous vasculitis and is degraded by chymase. Arch Dermatol Res 2016; 308 (08) 575-584
- 7 St John AL, Abraham SN. Innate immunity and its regulation by mast cells. J Immunol 2013; 190 (09) 4458-4463
- 8 Zhou T, Meadows V, Kundu D. et al. Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling. Hepatol Commun 2022; 6 (10) 2715-2731
- 9 Meadows V, Kennedy L, Hargrove L. et al. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice. Biochim Biophys Acta Mol Basis Dis 2019; 1865 (12) 165557
- 10 Hargrove L, Kennedy L, Demieville J. et al. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient KitW-sh mice. Hepatology 2017; 65 (06) 1991-2004
- 11 Jarido V, Kennedy L, Hargrove L. et al. The emerging role of mast cells in liver disease. Am J Physiol Gastrointest Liver Physiol 2017; 313 (02) G89-G101
- 12 Jones H, Hargrove L, Kennedy L. et al. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice. Hepatology 2016; 64 (04) 1202-1216
- 13 Kennedy LL, Hargrove LA, Graf AB. et al. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents. Lab Invest 2014; 94 (12) 1406-1418
- 14 Pham L, Kennedy L, Baiocchi L. et al. Mast cells in liver disease progression: an update on current studies and implications. Hepatology 2022; 75 (01) 213-218
- 15 Huang S, Wu H, Luo F. et al. Exploring the role of mast cells in the progression of liver disease. Front Physiol 2022; 13: 964887
- 16 Katsoulis-Dimitriou K, Kotrba J, Voss M, Dudeck J, Dudeck A. Mast cell functions linking innate sensing to adaptive immunity. Cells 2020; 9 (12) 2538
- 17
Krajewska NM,
Fiancette R,
Oo YH.
Interplay between mast cells and regulatory T cells in immune-mediated cholangiopathies.
Int J Mol Sci 2022; 23 (11) 23
MissingFormLabel
- 18 McDonald B, McAvoy EF, Lam F. et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J Exp Med 2008; 205 (04) 915-927
- 19 Jaeschke H, Farhood A, Fisher MA, Smith CW. Sequestration of neutrophils in the hepatic vasculature during endotoxemia is independent of beta 2 integrins and intercellular adhesion molecule-1. Shock 1996; 6 (05) 351-356
- 20 Bajt ML, Farhood A, Jaeschke H. Effects of CXC chemokines on neutrophil activation and sequestration in hepatic vasculature. Am J Physiol Gastrointest Liver Physiol 2001; 281 (05) G1188-G1195
- 21 Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediators Inflamm 2012; 949157
- 22 Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol 2017; 17 (04) 248-261
- 23 Madjene LC, Danelli L, Dahdah A. et al. Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitment. Kidney Int 2020; 97 (03) 516-527
- 24 Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 2008; 181 (08) 5598-5605
- 25 AhYoung AP, Eckard SC, Gogineni A. et al. Neutrophil serine protease 4 is required for mast cell-dependent vascular leakage. Commun Biol 2020; 3 (01) 687
- 26 Pejler G, Alanazi S, Grujic M. et al. Mast cell tryptase potentiates neutrophil extracellular trap formation. J Innate Immun 2022; 14 (05) 433-446
- 27 De Giovanni M, Tam H, Valet C, Xu Y, Looney MR, Cyster JG. GPR35 promotes neutrophil recruitment in response to serotonin metabolite 5-HIAA. Cell 2022; 185 (05) 815-830.e19
- 28 Liu K, Wang FS, Xu R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol 2021; 18 (01) 38-44
- 29 Tang J, Yan Z, Feng Q, Yu L, Wang H. The roles of neutrophils in the pathogenesis of liver diseases. Front Immunol 2021; 12: 625472
- 30 Minagawa N, Nagata J, Shibao K. et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007; 133 (05) 1592-1602
- 31 Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 2003; 125 (04) 1175-1187
- 32 Takeuchi M, Vidigal PT, Guerra MT. et al. Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis. Gut 2021; 70 (02) 342-356
- 33 Fabre T, Molina MF, Soucy G. et al. Type 3 cytokines IL-17A and IL-22 drive TGF-β-dependent liver fibrosis. Sci Immunol 2018; 3 (28) 3
- 34 Harty MW, Muratore CS, Papa EF. et al. Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am J Pathol 2010; 176 (03) 1271-1281
- 35 Calvente CJ, Tameda M, Johnson CD. et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest 2019; 129 (10) 4091-4109
- 36 Taïeb J, Delarche C, Paradis V. et al. Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. J Hepatol 2002; 36 (03) 342-348
- 37 Meadows V, Kennedy L, Ekser B. et al. Mast cells regulate ductular reaction and intestinal inflammation in cholestasis through farnesoid X receptor signaling. Hepatology 2021; 74 (05) 2684-2698
- 38 Ma YY, Yang MQ, Wang CF, Ding J, Li JY. Inhibiting mast cell degranulation by HO-1 affects dendritic cell maturation in vitro. Inflamm Res 2014; 63 (07) 527-537
- 39 Ma YY, Yang MQ, He ZG. et al. Upregulation of heme oxygenase-1 in Kupffer cells blocks mast cell degranulation and inhibits dendritic cell migration in vitro. Mol Med Rep 2017; 15 (06) 3796-3802
- 40 Xu JM, Shi GP. Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev 2012; 33 (01) 71-108
- 41 Bruneau A, Guillot A, Tacke F. Macrophages in cholangiopathies. Curr Opin Gastroenterol 2022; 38 (02) 114-120
- 42 Cadamuro M, Girardi N, Gores GJ, Strazzabosco M, Fabris L. The emerging role of macrophages in chronic cholangiopathies featuring biliary fibrosis: an attractive therapeutic target for orphan diseases. Front Med (Lausanne) 2020; 7: 115
- 43 Thankam FG, Dilisio MF, Dougherty KA, Dietz NE, Agrawal DK. Triggering receptor expressed on myeloid cells and 5'adenosine monophosphate-activated protein kinase in the inflammatory response: a potential therapeutic target. Expert Rev Clin Immunol 2016; 12 (11) 1239-1249
- 44 Labiano I, Agirre-Lizaso A, Olaizola P. et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. J Hepatol 2022; 77 (04) 991-1004
- 45 Guicciardi ME, Trussoni CE, Krishnan A. et al. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 2018; 69 (03) 676-686
- 46 Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106 (03) 259-262
- 47 Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2 (07) 585-589
- 48 Caron G, Delneste Y, Roelandts E. et al. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J Immunol 2001; 167 (07) 3682-3686
- 49 Mazzoni A, Siraganian RP, Leifer CA, Segal DM. Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol 2006; 177 (06) 3577-3581
- 50 Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. J Immunol 2006; 176 (07) 4102-4112
- 51 Shelburne CP, Nakano H, St John AL. et al. Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 2009; 6 (04) 331-342
- 52 Dawicki W, Jawdat DW, Xu N, Marshall JS. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J Immunol 2010; 184 (04) 2116-2123
- 53 Reuter S, Dehzad N, Martin H. et al. Mast cells induce migration of dendritic cells in a murine model of acute allergic airway disease. Int Arch Allergy Immunol 2010; 151 (03) 214-222
- 54 de Vries VC, Pino-Lagos K, Nowak EC, Bennett KA, Oliva C, Noelle RJ. Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 2011; 35 (04) 550-561
- 55 Skokos D, Botros HG, Demeure C. et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003; 170 (06) 3037-3045
- 56 Carroll-Portillo A, Cannon JL, te Riet J. et al. Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation. J Cell Biol 2015; 210 (05) 851-864
- 57 Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22 (11) 633-640
- 58 Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220
- 59 Orange JS, Salazar-Mather TP, Opal SM, Biron CA. Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol 1997; 71 (12) 9248-9258
- 60 Mikulak J, Bruni E, Oriolo F, Di Vito C, Mavilio D. Hepatic natural killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology. Front Immunol 2019; 10: 946
- 61 Male V, Stegmann KA, Easom NJ, Maini MK. Natural killer cells in liver disease. Semin Liver Dis 2017; 37 (03) 198-209
- 62 Portales-Cervantes L, Haidl ID, Lee PW, Marshall JS. Virus-infected human mast cells enhance natural killer cell functions. J Innate Immun 2017; 9 (01) 94-108
- 63 Shimoda S, Harada K, Niiro H. et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011; 53 (04) 1270-1281
- 64 Berent-Maoz B, Piliponsky AM, Daigle I, Simon HU, Levi-Schaffer F. Human mast cells undergo TRAIL-induced apoptosis. J Immunol 2006; 176 (04) 2272-2278
- 65 Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006; 43 (02) 362-372
- 66 Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin Exp Med 2008; 8 (01) 1-7
- 67 Takeda K, Kojima Y, Ikejima K. et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A 2008; 105 (31) 10895-10900
- 68 Sakanaka M, Tanaka S, Sugimoto Y, Ichikawa A. Essential role of EP3 subtype in prostaglandin E2-induced adhesion of mouse cultured and peritoneal mast cells to the Arg-Gly-Asp-enriched matrix. Am J Physiol Cell Physiol 2008; 295 (05) C1427-C1433
- 69 Ndaw VS, Abebayehu D, Spence AJ. et al. TGF-β1 suppresses IL-33-induced mast cell function. J Immunol 2017; 199 (03) 866-873
- 70 Jeong WI, Park O, Suh YG. et al. Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice. Hepatology 2011; 53 (04) 1342-1351
- 71 Tao X, Zhang R, Du R. et al. EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model. J Exp Med 2022; 219 (05) 219
- 72 Gasteiger G, Rudensky AY. Interactions between innate and adaptive lymphocytes. Nat Rev Immunol 2014; 14 (09) 631-639
- 73 Sun H, Sun C, Tian Z, Xiao W. NK cells in immunotolerant organs. Cell Mol Immunol 2013; 10 (03) 202-212
- 74 Hazenberg MD, Spits H. Human innate lymphoid cells. Blood 2014; 124 (05) 700-709
- 75 Yokota Y, Mansouri A, Mori S. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999; 397 (6721): 702-706
- 76 Spits H. Group 2 innate lymphoid cells show up in the skin. Immunol Cell Biol 2013; 91 (06) 390-392
- 77 Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12 (01) 21-27
- 78 Symowski C, Voehringer D. Interactions between innate lymphoid cells and cells of the innate and adaptive immune system. Front Immunol 2017; 8: 1422
- 79 Liu M, Zhang C. The role of innate lymphoid cells in immune-mediated liver diseases. Front Immunol 2017; 8: 695
- 80 Kim CH, Hashimoto-Hill S, Kim M. Migration and tissue tropism of innate lymphoid cells. Trends Immunol 2016; 37 (01) 68-79
- 81 McHedlidze T, Waldner M, Zopf S. et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013; 39 (02) 357-371
- 82 Li H, Zhan H, Cheng L, Yan S, Wang L, Li Y. Imbalanced distribution of group 2 innate lymphoid cells (ILCs) and ILC precursors in peripheral blood of patients with primary biliary cholangitis. Scand J Immunol 2022; 96 (01) e13166
- 83 Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179 (04) 2551-2555
- 84 Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998; 161 (09) 4866-4874
- 85 Lefrançais E, Duval A, Mirey E. et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 2014; 111 (43) 15502-15507
- 86 Liu J, Yang Y, Zheng C. et al. Correlation of interleukin-33/ST2 receptor and liver fibrosis progression in biliary atresia patients. Front Pediatr 2019; 7: 403
- 87 van der Ploeg EK, Hermans MAW, van der Velden VHJ, Dik WA, van Daele PLA, Stadhouders R. Increased group 2 innate lymphoid cells in peripheral blood of adults with mastocytosis. J Allergy Clin Immunol 2021; 147 (04) 1490-1496.e2